NCT07134842View on ClinicalTrials.gov

A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.

PHASE1RecruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 10, 2025

Primary Completion Date

January 1, 2027

Study Completion Date

January 1, 2028

Conditions
GlioblastomaGliosarcoma, AdultGlioblastoma - Category
Interventions
BIOLOGICAL

Ipilimumab (3 mg/kg)

All participants will be treated with ipilimumab (3mg/kg) for up to 2 cycles. Each cycle will last 21 days with participants receiving ipilimumab on the 1st day of the cycle.

Trial Locations (1)

NW1 2PG

RECRUITING

University College London Hospital, London

All Listed Sponsors
lead

University College, London

OTHER